112 related articles for article (PubMed ID: 33470694)
1. Changes in serum interferon-γ-inducible protein-10 levels and liver stiffness among chronic hepatitis C Egyptian patients in response to directly acting antiviral agents.
El-Nahaas SM; Rady NH; Malek S; Serag K
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e335-e340. PubMed ID: 33470694
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum interferon gamma inducible protein-10 as biomarker of fibrosis and predictor of virological response in genotype 4 hepatitis C virus infection.
Khalifa KA; Radwan WM; Attallah KM; Hosney H; Eed EM
Acta Gastroenterol Belg; 2014 Dec; 77(4):401-7. PubMed ID: 25682629
[TBL] [Abstract][Full Text] [Related]
3. IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy.
El Raziky M; Elsharkawy A; Said SE; Abdelatty S; El Akel W; Tantawy O; Gamal Eldeen H; Mabrouk M
J Interferon Cytokine Res; 2015 Aug; 35(8):649-53. PubMed ID: 25973761
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Interferon-γ (IFN-γ) and IFN-γ-Inducible Protein 10 (IP-10) Genes' Polymorphism on Risk of Hepatitis C Virus-Related Liver Cirrhosis.
Talaat RM; Elsharnoby S; Abdelkhalek MS; El-Shenawy SZ; Elmasry S
Immunol Invest; 2022 Apr; 51(3):688-704. PubMed ID: 33445993
[TBL] [Abstract][Full Text] [Related]
5. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
6. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Reiberger T; Aberle JH; Kundi M; Kohrgruber N; Rieger A; Gangl A; Holzmann H; Peck-Radosavljevic M
Antivir Ther; 2008; 13(8):969-76. PubMed ID: 19195322
[TBL] [Abstract][Full Text] [Related]
7. Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
Crisan D; Grigorescu MD; Radu C; Suciu A; Grigorescu M
Indian J Med Res; 2017 Apr; 145(4):543-550. PubMed ID: 28862188
[TBL] [Abstract][Full Text] [Related]
8. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
9. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
[TBL] [Abstract][Full Text] [Related]
10. Changes in Liver Stiffness and Noninvasive Fibrosis Scores in Egyptian Adolescents Successfully Treated with Ledipasvir-Sofosbuvir for Chronic Hepatitis C Virus Infection.
Fahmy DM; Shokeir M; El Zeiny SM; Jonas MM; Abdallah A
J Pediatr; 2021 Apr; 231():110-116. PubMed ID: 33347957
[TBL] [Abstract][Full Text] [Related]
11. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
[TBL] [Abstract][Full Text] [Related]
12. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
[TBL] [Abstract][Full Text] [Related]
13. Changes in the co-expressions of interleukin 29 (IL-29), IFN-inducible protein 10 (IP-10) and monokine induced by IFNγ (MIG) genes in chronic hepatitis C Egyptian patients untreated and treated with DAAs.
Gaballah A; Naga IS; Zaghloul MS; Mostafa HM; Noby A
Acta Virol; 2021; 65(2):141-148. PubMed ID: 34130465
[TBL] [Abstract][Full Text] [Related]
14. Serum inducible protein-10 chemokine as a biomarker for clearance of HCV with and without treatment in Egyptian patients.
Tabll A; El Shenawy R; Elsharkawy H; Mohamed FZ
Hum Antibodies; 2019; 27(4):265-273. PubMed ID: 31127759
[TBL] [Abstract][Full Text] [Related]
15. IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection.
Wang Y; Hu Y; Zhang X; Luo Y; Ma L; Lu J; Liang Q; Xu C; Zhao C; Pan CQ
Front Public Health; 2022; 10():911551. PubMed ID: 35923969
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.
Huang R; Rao H; Yang M; Gao Y; Wang J; Jin Q; Ma D; Wei L
Dig Dis Sci; 2020 May; 65(5):1491-1500. PubMed ID: 31654313
[TBL] [Abstract][Full Text] [Related]
17. Improvement of liver stiffness measurement, acoustic radiation force impulse measurements, and noninvasive fibrosis markers after direct-acting antivirals for hepatitis C virus G4 recurrence post living donor liver transplantation: Egyptian cohort.
Alem SA; Said M; Anwar I; Abdellatif Z; Elbaz T; Eletreby R; AbouElKhair M; El-Serafy M; Mogawer S; El-Amir M; El-Shazly M; Hosny A; Yosry A
J Med Virol; 2018 Sep; 90(9):1508-1515. PubMed ID: 29718546
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
19. Predictors for Fibrosis Regression in Chronic HCV Patients after the Treatment with DAAS: Results of a Real-world Cohort Study.
Soliman H; Ziada D; Salama M; Hamisa M; Badawi R; Hawash N; Selim A; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):104-111. PubMed ID: 31448717
[TBL] [Abstract][Full Text] [Related]
20. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
